Catalyst Wire Dossier Catalyst Wire Dossier

ETBX-021 Ad5 [E1-, E2b-]-HER2/Neu vaccine

Ad5 [E1-, E2b-]-HER2/Neu vaccine · NantBioScience, Inc.
Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for ETBX-021 Ad5 [E1-, E2b-]-HER2/Neu vaccine, covering 2025-01-13 to 2025-01-13. Get the full timeline:

Most recent: Clinical Trial Update: QUILT-3.013: Study of Ad5 [E1-, E2b-]-HER2/Neu Vaccine (ETBX-021) in Subjects With Unresectable Locally Advanced or Metastatic HER2-Expressing Breast Cancer [Phase 1]

See pricing